Ying Wei, Xiaolin Wang, Zhe Zhang, Mingrui Xie, Yuyao Li, Hongxin Cao and Xinhan Zhao* Pages 579 - 588 ( 10 )
<P>Background: Single-nucleotide polymorphisms (SNPs) are important indicators of susceptibility to breast cancer. </P><P> Objective: To assess the associations between SNPs in the FAM13A, PHLDB1, and CYP24A1 gene and breast cancer risk in the Chinese Han population. </P><P> Methods: We performed a case-control study including 379 female breast cancer patients and 407 female healthy controls. The three SNPs were genotyped using Agena MassARRAY platform. The χ2 test was used to compare alleles and genotypes frequencies of polymorphisms between case and control groups. Genetic models analyses to assess the associations between SNPs and breast cancer risk by computing odds ratios (ORs) and 95% confidence intervals (CIs) using logistic regression. RegulomeDB and HaploReg databases were used to calculate possible functional effects of polymorphisms. </P><P> Results: Overall analysis results showed that rs4809957 was associated with an increased risk of breast cancer (allele A: OR = 1.27, 95% CI: 1.03-1.55, p = 0.024; AA vs. GG: OR = 1.80, 95% CI: 1.15–2.82, p = 0.010; recessive model: OR = 1.70, 95% CI: 1.12–2.58, p = 0.012); and rs1059122 was found to be associated with a reduced breast cancer risk in the recessive model (OR = 0.71, 95% CI: 0.51–0.98, p = 0.039). Stratification analysis found significant associations between the three SNPs (rs1059122, rs17748, and rs4809957) and breast cancer risk. </P><P> Conclusion: Our results suggested that rs1059122 (FAM13A), rs17748 (PHLDB1), and rs4809957 (CYP24A1) might contribute to breast cancer susceptibility in the Chinese Han population. Future studies with large samples are required to confirm our findings, as well as functional studies are needed to explore their function in the breast cancer development.</P>
Breast Neoplasms, FAM13A, PHLDB1, CYP24A1, single nucleotide polymorphisms, cancer.
Department of Internal Medicine Oncology, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710061, Department of General Surgery, The Second Hospital of Yulin City Shaanxi Province, Yulin, Shaanxi 719000, Department of General Surgery, The Second Hospital of Yulin City Shaanxi Province, Yulin, Shaanxi 719000, Department of Internal Medicine Oncology, The Second Hospital of Yulin City Shaanxi Province, Yulin, Shaanxi 719000, Department of Internal Medicine Oncology, The Second Hospital of Yulin City Shaanxi Province, Yulin, Shaanxi 719000, Department of Internal Medicine Oncology, The Second Hospital of Yulin City Shaanxi Province, Yulin, Shaanxi 719000, Department of Internal Medicine Oncology, The First Affiliated Hospital of Xi'an Jiaotong University School of Medicine, Xi'an, Shaanxi 710061